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doi:10.1Objective: Balancing longer duration of mechanical circulatory support while awaiting functional recovery
against the increased risk of adverse events with each day on support is difficult. Therefore, we investigated
the complex interplay of duration of mechanical circulatory support and patient and device factors affecting sur-
vival on support, as well as survival after transplantation.
Methods: From December 21, 1991, to July 1, 2006, mechanical circulatory support was used in 375 patients as
a bridge to transplantation, with 262 surviving to transplant. Implantable pulsatile devices were used in 321 pa-
tients, continuous flow was used in 11 patients, a total artificial heart was used in 5 patients, external pulsatile
devices were used in 34 patients, and extracorporeal membrane oxygenation was used in 68 patients. Two
time-related models were developed: (1) a competing-risks multivariable model of death on mechanical circula-
tory support, with modulated renewal for each sequential support mode; and (2) a model of death after transplant
in which patient factors and duration of mechanical circulatory support were investigated as risk factors.
Results: Survival after initiating mechanical circulatory support, irrespective of transplantation, was 86% at 30
days, 55% at 5 years, and 41% at 10 years; survival was 94%, 74%, and 58% at the same time intervals, respec-
tively, after transplantation in those surviving the procedure. Risk factors for death included longer, but not shorter,
duration of mechanical circulatory support, use of multiple devices, global sensitization, and poor renal function.
Conclusion: Initiating mechanical circulatory support early with a single definitive device may improve survival
to and after cardiac transplantation. Early transplant, which avoids infection, sensitization, and neurologic com-
plications, may improve bridge and transplant survival. (J Thorac Cardiovasc Surg 2010;139:1295-305)Supplemental material is available online.
Large multicenter heart transplant databases consistently
identify duration of mechanical circulatory support (MCS)
as a risk factor for posttransplant mortality,1–3 but determin-
ing optimal timing of transplantation after bridging is diffi-
cult. We and others have recommended supporting patients
1 to 3 months for organ and functional recovery to maximize
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Xare data from the Cardiac Transplant Research Database,
International Society for Heart and Lung Transplantation,
and United Network for Organ Sharing (UNOS) that consis-
tently demonstrate reduced survival if transplantation occurs
within 2 weeks or after 6 months of initiating MCS.5,6
Although there are intuitive merits to waiting, we questioned
its validity when risk factors and complications not present at
initiation of support delayed transplantation or when device
failures or device-related strokes or infections forced urgent
transplantation. Previous studies focusing only on survival
after transplantation of bridged patients have not accounted
for this morbidity and mortality during MCS; doing so
may influence optimal timing of transplantation. Therefore,
we investigated the complex interplay of duration of MCS
and patient and device factors affecting survival on MCS,
as well as survival after transplantation.PATIENTS AND METHODS
Patients
From December 21,1991, to July 1, 2006, 375 patients determined to be
transplant candidates were supported with multiple forms of MCS as
a bridge to transplantation. Of these, 262 received transplants through De-
cember 2006. Patients on MCS who at the outset were not transplant candi-
dates or were bridged to recovery were excluded.
Data
Primary data were collected concurrently with patient care as part of the
Unified Transplant Database, Cardiovascular Information Registry, anddiovascular Surgery c Volume 139, Number 5 1295
Abbreviations and Acronyms
ECMO ¼ extracorporeal membrane oxygenation
HLA ¼ human leukocyte antigen
LVAD ¼ left ventricular assist device
MCS ¼ mechanical circulatory support
PRA ¼ panel reactive antibody
UNOS ¼ United Network for Organ Sharing
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XTransplant and Allogen databases. All have been approved for use in research
by the institutional review board, with patient consent waived. Charts were
reviewed to confirm data or add missing values. Using these, we investigated
pre-device, post-device, and transplant variables, patient demographic and
clinical characteristics (Table 1), device type, and complications after device
insertion. Three variables deserve specific elaboration.TABLE 1. Patient characteristics
At MCS
Characteristic ny No. (%) or mean ± SD ny
Demography
Age (y) 375 53  12 262
Female 375 65 (17) 262
Race 374 261
Caucasian 326 (87)
African-American 41 (11)
Other 7 (1.9)
Height (cm) 366 174  9.08 263
Weight (kg)z 282 83  18 262
Comorbidity
Creatinine (mg/dL)z 322 1.72  0.88 255
Bilirubin (mg/dL)z 314 1.73  1.38 229
BUN (mg/dL)z 318 38  22 252
Hematocrit (%)z 288 33  5.3 165
Hemoglobin (mg/dL)z 195 19  11 182
BP in systole (mm Hg)z 239 96  17 68
BP in diastole (mm Hg)z 229 57  12 68
T-PRA>10% 239 40 (17)
Cardiac indexz 265 1.87  0.46
Cardiogenic shockz 306 134 (44) 68
Previous cardiac surgery 338 149 (44)
Indication for transplant
Ischemic cardiomyopathy 375 223 (59) 262
Dilated cardiomyopathy 375 126 (34) 262
Other 375 26 (6.9) 262
Support 262
IABP 375 304 (81)
Inotropes 346 312 (90)
Ventilator 375 294 (78)
Medical condition 312 252
ICU 309 (99)
Home (not hospital) 1 (0.32)
Hospital (not ICU) 2 (0.64)
BP,Bloodpressure;BUN, bloodurea nitrogen; IABP, intra-aortic balloonpumping;MCS,mech
*Value at time ofMCSminus value at time of transplant. yData available. zData collected with
time ofMCS and 11 (4.9%) remained on IABP until transplant. kOf 262 patients who had a tra
inotropes until transplant. {Of 262 patients who had a transplant, 218 (83%) were on a ven
1296 The Journal of Thoracic and Cardiovascular SurNumber of devices. Number of devices represents the sequence of
modes of MCS required for cardiopulmonary stabilization; 267 patients
had only 1 device, 87 patients had 2 devices, 19 patients had 3 devices,
and 2 patients had 4 devices (Figure 1). Initiation of MCS was considered
the first device regardless of its traditional designation as a ‘‘short-’’ or
‘‘long-term’’ device. We chose to do this because (a) characterization of
the terms ‘‘short-’’ and ‘‘long-term’’ for devices is arbitrary and inconsis-
tently used; (b) time zero for bridging began when the first device was in-
serted; (c) 9 patients underwent transplantation directly from short-term
MCS (extracorporeal membrane oxygenation [ECMO] and Abiomed
BVS 5000 systems [ABIOMED, Inc, Danvers, Mass); and (d) we wanted
to determine whether sequential devices affected survival to and after trans-
plantation (Figure 2), and the study was designed to assess survival from the
time of MCS initiation.
Global sensitization. Defining sensitization during MCS is com-
plex. Panel reactive antibody (PRA) screening methods and threshold for
treatment vary widely among centers,7 and PRA levels duringMCS are vol-
atile and nonspecific, increasing early after MCS initiation and returning toAt transplant Change* from MCS to transplant
No. (%) or mean ± SD (15th/50th/85th percentiles)
53  11 —
39 (15) —
230 (88) —
28 (11) —
3 (1.2) —
174  8.6 0.04/0.0/0.0
85  16 0.1/0.0/0.0
1.2  0.56 0.2/0.3/1.0
0.92  1.01 0.2/0.6/1.7
21  13 4/11/36
30  4.7 3.7/3.0/9.2
17  10 1.7/1.7/7.1
122  23 63/28/1
65  12 25/11/4
— —
— —
2 (2.9) —
— —
156 (60) —
90 (34) —
16 (6.1) —
16 (6.1) —x
27 (10) —k
16 (6.1) —{
176 (70) —
49 (19) —
27 (11) —
anical circulatory support; SD, standarddeviation;T-PRA,T-cell panel reactive antibody.
in 72 hours of transplant. xOf 262 patients who had a transplant, 223 (85%) had IABP at
nsplant, 225 (86%) were receiving inotropes at time ofMCS and 23 (10%) remained on
tilator at time of MCS and 11 (5.0%) remained on a ventilator until transplant.
gery c May 2010
FIGURE 1. Sequence of MCS. The volume of each sphere is proportional to the number of patients who received that support device.
Smedira et al Cardiothoracic Transplantation
T
Xbaseline within weeks.8 Identifying the quantity and specificity of human
leukocyte antigen (HLA) antibodies has improved with evolution from
complement activation cytotoxicity (standard definition of PRA> 10%)
to cellular flow cytometry to single HLA bead flow cytometry. Specific
high-level antibody presence was determined by histocompatibility experts
who recommended desensitization and immunosuppressive therapies.
Thus, global sensitization was defined as presence of T-cell PRA more
than 10% or high levels of antibody against specific HLA antigens. These
patients are managed with pretransplant plasmapheresis or use of induction
therapy with OKT3 or antithymocyte globulin.
Cardiogenic shock. Of our 375 patients, 306 had adequate data
available to classify them as being in cardiogenic shock or not (defined as
systolic blood pressure<80 mm Hg or cardiac index<1.8 L/m2). Of the
306 patients, 134 (44%) were in cardiogenic shock at the initiation of
MCS. Of these patients, 123 (92%) were initially supported with a left ven-
tricular assist device (LVAD), 8 (6%) with ECMO, 2 (1.5%) with a biven-
tricular assist device, 1 (0.75%) with a total artificial heart, and 0 (0%) with
a right ventricular assist device.The Journal of Thoracic and CarEnd Points and Strategy
Survival was assessed 3 ways: (1) overall, with time zero being inception
of MCS; (2) on MCS to transplantation; and (3) after transplantation. Post-
transplant survival and cause of death were determined as part of annual
UNOS follow-up using UNOS definitions for cause of death (see www.
unos.org). Mean follow-up was 6.2  3.7 years, with 1402 patient-years
of data available for analyses.Data Analysis
Strategy. Analytic strategy was that of a multistate, competing-risks
process, with modulated renewal for each sequential mode of support.9 Spe-
cifically, death on MCS and transplantation were considered competing
risks. However, the hazard functions for death onMCS after each sequential
mode had similar time-varying contours, suggesting modulated renewal.
This permitted incorporating into the analysis of death on MCS cumulative
events occurring with previous modes. Death after transplant was the final
state considered. In addition, overall all-cause mortality after initiatingMCSdiovascular Surgery c Volume 139, Number 5 1297
FIGURE 2. Survival while on eachMCS device. This so-called modulated renewal format censors patients when another device is used or transplant occurs.
Time zero is reset at each sequential change in mode of MCS. Each symbol represents a death, vertical bars represent 68% confidence limits (equivalent to1
standard error), and numbers in parentheses represent patients remaining at risk.
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Xprovided, irrespective of whether the patient underwent transplantation, an
estimate of salvage of patients after initiating MCS. Survival was estimated
nonparametrically by the Kaplan–Meier method and parametrically by haz-
ard function decomposition.10 (For additional details, see http://www.
clevelandclinic.org/heartcenter/hazard.)
Multivariable analyses. Multivariable analyses were performed in
the hazard function domain using bagging for variable selection.11 Briefly,
500 bootstrap data sets were analyzed by automated stepwise variable selec-
tion at P¼.05. These models were aggregated by selecting variables appear-
ing in approximately 50% or more of models. Incremental risk factor table
entries are accompanied by an estimate of Reliability (%), which quantifies
the probability that the P value given in the table is actually less than .05.
Pre-MCS variables considered in variable selection for death onMCS are
listed in Appendix E1. In addition, for each modulated renewal segment,
MCS sequence number; mode; whether support was left sided, right sided,
or both; sequence of devices used; duration of previous segment; accumu-
lated time on MCS; and adverse nonfatal events occurring before that mode
were examined. These time-varying covariables are directly and simply in-
corporated in the context of modulated renewal.
Pretransplant variables considered in variable selection for death after
transplant are listed inAppendix E1. Of note, these included variables related
toMCSmodes, adverse events while onMCS, changes in variables while on
MCS, and sensitization variables. As prespecified, duration of MCS was
forced into this model, and investigation of polynomial transformations of
scale was made to detect the previously described2 peaking relationship.
Optimal timing of transplant. We conventionally chose to por-
tray 5-year survival after initiation of MCS as a function of its duration.
The probability of surviving both MCS and transplantation is the product
of survival after initiating MCS (duration of MCS) and survival after trans-
plantation at 5 years minus duration of MCS.
In addition to non–risk-adjusted portrayals, we have simulated a number
of scenarios based on risk factors for death on MCS and after transplant. A
baseline low-risk patient was defined as aged 54 years with a body surface
area of 2.04 m2, pre-MCS creatinine level of 1.7 mg/dL, pre-MCS bilirubin
level of 1.74 mg/dL, pre-MCS diastolic blood pressure of 58 mm Hg,
pre-MCS pulmonary artery systolic pressure of 52 mm Hg, cardiac index
of 1.9 L/min/m2, pre-MCS intraaortic balloon pump, pretransplant blood1298 The Journal of Thoracic and Cardiovascular Sururea nitrogen of 19 mg/dL, no previous cardiac operation, single MCS (not
LVAD), MCS duration of 2.5 months, and a neurologic complication while
onMCS. A series of nomograms were constructed on the basis of changes to
these baseline characteristics, which are specified in Figures 3 and 4.
RESULTS
Risk-Unadjusted Survival
Risk-unadjusted survival after initiating MCS, irrespec-
tive of transplantation, was 86% at 30 days, 69% at 6
months, 65% at 1 year, 55% at 5 years, and 41% at 10 years
(Figure 5). Risk-unadjusted survival on MCS before trans-
plantation was 84% at 1 month, 73% at 3 months, 62% at
6 months, and 45% at 12 months (Figure E1); however,
half the patients were supported less than about 2 months
and 10% of patients were supported for more than 6 weeks.
Of 262 patients surviving to transplantation, subsequent risk-
unadjusted survival was 94% at 30 days, 74% at 5 years, and
58% at 10 years (Figure E2). Two hazard phases were re-
solved: a high early phase that gave way to a constant hazard
approximately 1 month after transplant.
Risk Factors for Death on Mechanical Circulatory
Support
Both younger and older patients (Figure 3, A) and those
who received non-LVAD devices (Figure 3, B) were at
higher risk of dying onMCS (Table 2). Survival onMCS de-
creased more rapidly with each sequential mode of MCS
(Figure 4). Patients who had lower pulmonary arterial pres-
sures experienced better survival. Any MCS mode other
than an LVAD at MCS initiation (Figure E3, A, B) was as-
sociated with considerably higher risk of death. Of note,
the specific sequence of devices and duration of supportgery c May 2010
FIGURE 3. Predicted 6-month survival on MCS. Depicted are baseline patient characteristics and differences in age. A, Survival according to age. B, Sur-
vival according to age and whether or not the patient was on LVAD support.
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Xdid not increment risk above that already accounted for by
sequence number and mode of support.
Risk Factors for Death After Transplantation
Early transplantation (short MCS duration) did not ad-
versely affect posttransplant survival, and there were no sta-
tistically significant survival differences with respect to
clinical characteristics between the 44 patients (17%) who
underwent transplantation within 4 weeks of initiating
MCS and those undergoing transplantation later. Longer du-
ration of support adversely affected posttransplant survival,
although this relation could be due to chance (23% probabil-
ity that P <.05), despite an apparently small P valueThe Journal of Thoracic and Car(Table 3). We found only a 4% chance (Reliability) that
the relationship between duration of support and posttrans-
plant survival could be peaking. In addition, more sequential
modes of MCS used, greater number of infections, and
global sensitization were all associated with reduced sur-
vival after transplantation (Tables 3 and 4).
Bridge-to-Transplant Survival
Overall, accounting simply for duration of MCS, the
probability of surviving both MCS and transplantation was
69% at onset of MCS, 65% at 1 month, 56% at 3 months,
47% at 6 months, and 29% at 12 months (Figure E4). These
percentages were substantially altered by both patient- anddiovascular Surgery c Volume 139, Number 5 1299
FIGURE 4. Five-year survival after transplant according to duration of MCS for a low-risk patient. Dashed lines represent 68% confidence limits of upper
and lower curves. A, Survival simulated according to whether or not global sensitization had occurred on MCS. B, Survival after transplant simulated by
number of devices implanted and subsequent transplantation.
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Xdevice-related risk factors. Survival of a low-risk patient
(baseline scenario; see ‘‘Optimal Timing of Transplant’’ un-
der ‘‘Patients and Methods’’) was greatly affected by being
globally sensitized or number of devices received (Figures 2
and 4, A, B).DISCUSSION
Principal Findings
Transplant outcomes are strongly influenced by both pre-
and post-MCS risk factors and events. Previous cardiac op-
eration, need for ECMO or right ventricular assist device,
poor renal function, HLA sensitization, and neurologic com-
plications reduced survival after transplantation. Longer1300 The Journal of Thoracic and Cardiovascular SurMCS duration did not improve survival before transplant
and may worsen survival after transplant.Survival
Survival to and after transplant and overall survival after
initiation of MCS was excellent and similar to other reports,
even with inclusion of patients on short-term support.12 Sur-
vival difference between low- and high-risk groups was sur-
prisingly large and similar in magnitude to a comparison of
low- and high-risk patients supported long term with the
HeartMate XVE device (Thoratec Corp, Pleasanton,
Calif).13,14 Renal dysfunction and sepsis were 2 risk factors
affecting survival. Longer duration of MCS may decreasegery c May 2010
FIGURE 5. Overall survival after initiating MCS, regardless of time of transplant. Format is as in Figure 2.
Smedira et al Cardiothoracic Transplantationsurvival to and after transplantation independently of other
complications. This suggests that a cumulative burden of
low- and high-frequency MCS complications (eg, device
malfunctions and disconnects), patient and device mishaps
(eg, cutting drivelines or simultaneously disconnecting bat-
teries), and strokes and anticoagulation-related hemorrhages
slowly diminish survival before and after transplantation.15
This has important implications for new-generation device
management. Although continuous-flow pumps have fewer
overall complications, these have not been eliminated and
will continue to affect survival to and likely after transplan-
tation. John and colleagues,16 for example, demonstrated
that increased red blood cell transfusions and driveline infec-
tion with the Heartmate II device (Thoratec Corp) reduced
survival after transplantation.T
XSequence of Mechanical Circulatory Support
Sequential application of devices was associated with
markedly reduced survival. Initiating MCS early with a sin-
gle definitive device may improve survival before and after
cardiac transplantation. Notably, the specific sequence of de-
vices and duration of support did not increase risk above that
already accounted for by the sequence number or choice of
device type. This emphasizes, as Fitzpatrick and col-
leagues17 have shown, that survival is primarily determined
by an early decision to implant univentricular or biventricu-
lar devices and not by choice of device type.Duration of Mechanical Circulatory Support
We did not find a risk of early transplantation after initiat-
ing MCS, despite 17% of patients (n ¼ 44) undergoingThe Journal of Thoracic and Cartransplantation within 4 weeks. Pre-MCS characteristics of
these patients were similar to those of patients undergoing
transplantation later. Survival before and after initiation of
MCS was relatively flat, with mortality increasing after 4
months of support. This finding is similar to that reported
by John and colleagues,16 who studied the impact of dura-
tion of support for patients bridged with the HeartMate II de-
vice on survival. They observed excellent survival in the
small group of patients who underwent transplantation in
less than 30 days and found a trend toward increased mortal-
ity in those supported for more than 12 months. They spec-
ulated that this trend with longer duration of support could
be due to sensitization.
Survival of the entire bridging program from initiating
MCS through transplantation is rarely shown in the literature.
However, this is the total risk to which a patient is exposed.
The fact that a patient remains on support for more than 4
months at the Cleveland Clinic, when our average overall
wait time as reported by the Scientific Registry of Transplant
Recipients (www.ustransplants.org) is 2.7 months, and 2.5
months for patients on MCS (Figure E5), raised the
possibility that longer duration of MCS was a surrogate for
some mitigating circumstance delaying transplantation. Two
possible explanations are the need to treat sensitization and
infections; however, these complications did not occur more
frequently in patients with longer durations of MCS, and
sensitization independently reduced posttransplant survival.Sensitization
There is general consensus that MCS increases the likeli-
hood of sensitization.18–20 However, there is disagreement asdiovascular Surgery c Volume 139, Number 5 1301
TABLE 4. Adverse events occurring on mechanical circulatory
support
Event n* No. (%)
Adverse events on MCS (n ¼ 375)
Neurologic 363 100 (28)
Infection
Driveline 363 73 (20)
Pump-pocket 363 53 (15)
Other 363 98 (27)
Reoperation for bleeding 363 91 (25)
Device failure 363 15 (4.1)
Adverse MCS events among transplant recipients (n ¼ 262)
Neurologic 252 57 (23)
Infection
Driveline 252 67 (24)
Pump-pocket 252 41 (16)
Other 252 57 (23)
Reoperation for bleeding 252 57 (23)
Device failure 252 8 (3.2)
Global sensitization 253 137 (59)
MCS, Mechanical circulatory support. *Data available.
TABLE 2. Incremental risk factors for death on mechanical
circulatory support
Factor Estimate ± SE P
Reliability
(%)*
Early hazard phase
More devices 1.2  0.25 <.0001 87
Pre-MCS higher BP at diastoley 1.1  0.49 .02 45
Pre-MCS higher creatininez 1.7  0.75 .03 57
Pre-MCS higher bilirubin 0.40  0.14 .006 59
ECMO or RVAD 2.8  0.69 <.0001 96
Late hazard phase
Age 57
Younger agex 1.3  0.28 <.0001
Older agek 1.8  0.42 <.0001
Pre-MCS lower cardiac index{ 3.7  1.1 .0006 69
Pre-MCS lower PA pressure at
systole#
1.6  0.61 .008 54
Pre-MCS higher creatinine** 0.087  0.022 <.0001 74
Neurologic complication 1.6  0.61 .003 42
BP, Blood pressure; BSA, body surface area; ECMO, extracorporeal membrane oxy-
genation; IABP, intra-aortic balloon pumping; MCS, mechanical circulatory support;
PA, pulmonary artery; RVAD, right ventricular assist device; SE, standard error. *Per-
cent of times factor appeared in 500 bootstrap analyses. y(BP at diastole/60)2, squared
transformation. z(1/creatinine), inverse transformation. x(50/age), inverse transforma-
tion. k(Age/50)2, squared transformation. {(1/cardiac index), inverse transformation.
#Log(PA pressure at systole), logarithmic transformation. **(Creatinine)2, squared
transformation.
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Xto its importance.21,22 This disagreement in part reflects var-
iability in the type of test used, its interpretation, and the fact
that HLA antibodies after MCS are for the most part nonspe-
cific. Because the majority of the hearts we use are imported,
precluding prospective cross-matching of sensitized pa-
tients, we have used ‘‘virtual matching,’’ comparing donor
HLA type with known quantities of specific anti-donor
HLA antigens.23 Although this facilitates transplantation,
30% of our patients receiving imported hearts have some de-
gree of weakly positive posttransplant cross-matches as de-
termined by flow cytometry,23 and this is associated withTABLE 3. Incremental risk factors for death after transplantation
among mechanical circulatory support patients surviving to
transplantation
Factor Estimate ± SE P Reliability (%)*
Early hazard phase
More modes of MCS 1.5  0.53 .005 40
More blood infections 0.31  0.092 .0008 61
Late hazard phase
Longer duration on MCS (y)y 0.85  0.15 <.0001 23
More neurologic complications 0.43  0.17 .01 51
Global sensitizationz 0.56  0.26 .03 51
Poor renal functionx 0.32  0.502 <.0001 68
Previous cardiac operation 0.75  0.25 .003 64
MCS,Mechanical circulatory support; SE, standard error; T-PRA, T-cell panel reactive
antibody. *Percent of times factor appeared in 500 bootstrap analyses. y(Duration on
MCS)2, squared transformation. zAny of the following: specifically sensitized, need-
ing plasmapheresis, needing induction therapy, T-cell PRA>10%. xExp(blood urea
nitrogen at transplant/40), exponential transformation.
1302 The Journal of Thoracic and Cardiovascular Suran increased frequency of humoral, acute, and chronic cellu-
lar rejection and decreased survival.24
Strengths and Limitations
This was an observational study encompassing 15 years,
during which multiple surgeons cared for patients, and nu-
merous devices, clinical practices, and therapies were intro-
duced and others abandoned. Confounding our analysis
effort was nonstandardized approaches to MCS, variable as-
sessment and treatment of sensitized patients, induction ther-
apy and plasmapheresis, which can suppress immune
function, and unrecognized surgical biases for a specific de-
vice and timing of transplantation. One of the study’s
strengths, however, is that a substantial number of patients
underwent transplantation after a short duration of MCS.
We did not measure quality-adjusted life years, mental
and emotional status, or costs, all of which may be important
outcomes from patient, payor, and society perspectives. We
did not, in this subset of transplant recipients, investigate do-
nor variables that are well known to affect survival after
transplantation, particularly in sensitized patients. There
may be institutional or individual confounding effects on re-
sults. Finally, only 11 patients in our cohort were supported
with continuous-flow pumps. Recent reports have demon-
strated this technology to be more durable and reliable
than pulsatile support, and although not totally eliminated,
pump thrombosis, thromboembolism, and device-related in-
fection seem to be lower than with pulsatile support (at 18
months post-implant).25
CONCLUSIONS
Our study suggests that initiating MCS early and with
a single definitive mode of support may improve survivalgery c May 2010
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Xbefore and after transplantation. Performing transplantation
in the patient as soon as possible, not necessarily fully recov-
ered, may be prudent. Although virtual cross-matching is
convenient, it requires further validation before replacing
prospective cross-matching in highly sensitized individuals.
Initiating MCS early with a single definitive device may im-
prove survival to and after cardiac transplantation. Early
transplant, which avoids infection, sensitization, and neuro-
logic complications, may improve bridge and transplant sur-
vival.
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Discussion
Dr J. Kirklin (Birmingham, Ala). This is an elegant and sophis-
ticated analysis that takes on a complex and controversial issue in
cardiac transplantation. As you know, Nick, we previously ana-
lyzed the information from the Cardiac Transplant Research Data-
base, and as you did at the Cleveland Clinic, we found that there
was a progressive increase in risk for the longer duration of support
before cardiac transplantation. The one difference was that we also
found an increased risk, as have some other studies, in the first 2
weeks more or less. So this is the crux of the matter in this analysis.
Many transplant centers, and in fact most now, have a general pol-
icy of more or less 30 days, if the patient is, as you say, ambulatory
and his/her subsystem dysfunction is reversed, to go ahead and acti-
vate for transplantation.So the real core of the issue of a potential con-
troversy exists in that first 3 to 4 weeks. To enlighten us and help us
analyze or perhaps judge the efficacy of yourmodel in really address-
ing that first period after the patient receives the device, 2 questions.
Many other analyses have indicated that increasing risk of dura-
tion of time on support has a major effect on the early phase of risk
after cardiac transplantation. We found that for both increase in du-
ration of support and very early transplantation. To what do you at-
tribute your finding that it was only operative in the late phase of
hazard after cardiac transplantation, which I find a little bit curious?
Second, and more important, you mention in your article that
17% of the patients actually underwent transplantation within 30
days of receiving their device. So this is the cohort of special inter-
est. Did you have the opportunity to look specifically at the patient
characteristics or profiles of that 17% who actually had a transplant
within 30 days of the device? For example, were these so-called IN-
TERMACS class I, in cardiogenic shock, did they receive ECMO
support or other short-term device, and if so, what really played in
the clinician’s mind to allocate transplantation of them early as op-
posed to switching to a more durable device? And for those who
had a durable device, what were the patient profiles? Do we have
evidence they had insufficient reversal of organ dysfunction at
the time you performed transplantation that would help supportdiovascular Surgery c Volume 139, Number 5 1303
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reversal of organ dysfunction?
Dr Smedira. Thanks, Jim, for your comments, and I would first
like to take this opportunity to recognize Dr Kirklin for his contri-
butions, both the transplant database and nowwith the development
of the INTERMACS registry, which I think will help enlighten us
and answer some of these questions. Let me answer 2 first and then
go back and speculate on the first question.
Seventeen percent of our patients underwent transplantation
within 4 weeks. Nine of our patients underwent transplantation
off of ECMO or the BVS 5000 system (ABIOMED, Inc, Danvers,
Mass). We could not find anything that distinguished those cohorts
receiving transplants early or late. There were no distinguishing
characteristics. I think it was the philosophy of the surgeons that
this person was best served by going straight to transplantation.
That is a surprise to me, because even within my own institution
I didn’t think we were doing that, but in fact my colleagues were,
and the results weren’t bad.
As for implantable devices, as I said, I used to hold the bar up to
15minutes on the treadmill before I would activate a patient. Again,
my colleagues would go sooner. And so I think the way I put this
together is if the patient has recovered organ function, is ambula-
tory and doing well, there is really no contraindication to proceed
with transplantation. It was difficult to define anything unique
about these early transplant recipients.
Now, why do they have a decrement at 3 to 5 years? I looked
closely at your article in the Journal, and you showed there was
a relative risk of approximately 1.46 in those undergoing transplan-
tation after 6 months, if I remember correctly, and you said your
early phase went from 30 days to 2 years. Now, my best guess is
it is probably some immune-mediated problem related to the de-
vice. Now, most of our patients had HeartMate devices, and we
had some Novacor devices (World Heart Inc, Salt Lake City,
Utah), and there is a great deal of information about the device sur-
face activating the immune system. So my best guess for why this
would be showing up at the 2- to 3-year mark is some immune ac-
tivation. We saw that it was much worse in the patients who were
infected and sensitized, and we know those patients are immune-
activated. So I think it is a synergistic activation of those factors.
Dr J. Conte (Baltimore, Md). Nick, a very nice presentation, but
as I was sitting here listening, I am really not sure what the take-
home message is. My current practice is to put the ventricular assist
device in; the patient recovers, is discharged, and returns to the
clinic every week thereafter; and once the patient mentally and
physically feels good, and the laboratory values are good, we think
the patient has recovered. If the patient is walking around, doing
well at home, then we list him/her for transplantation. A couple
of years ago that is what UNOS told us was appropriate for us to
now begin the patient’s status 1a time. Once the transplant team
thought the patient was ready for transplant, we could go ahead
and list him/her.
If you have a patient who is doing well after ventricular assist de-
vice implantation, at what point exactly are you saying we ought to
perform transplantation in these patients? Because we may be do-
ing the same thing. I am not really sure what you are doing, but
could you be specific about that?
Dr Smedira. Let me address the first part of that. What we saw
in these patients who are discharged, brought back, and are doing1304 The Journal of Thoracic and Cardiovascular Surfine and everything is looking good, is that we lose patients as
we wait for them to become perfect candidates. We have had pa-
tients whom we wanted to recover a bit and learn a bit more how
to deal with their device, and they have died of strokes before we
were able to activate them. Any of you in the business has seen
the recent notifications of HeartMate II outflow cannula disconnect
where the patient died. We had a recent patient who just required an
emergency operation because fluid was aspirated in the vent. My
impression is the longer you keep patients on the device, you run
the risk of device and patient interaction and malfunction, and
you will lose some patients. When the patient is, to your best esti-
mate, ready to undergo another operation, he/she should be acti-
vated for transplantation with the bar not set excessively high.
DrConte. I think I agree with you, but what time are you saying?
Dr Smedira. Our study says it doesn’t matter. And I know my
colleague, Dr Banbury, is here, and if he saw the patient was sitting
up and could move around, it is time to undergo transplantation.
Could be 2 weeks, 7 days, 10 days, a different approach. In our
analysis, going in early, within 4 weeks, did not affect survival.
Dr Conte. The paradigm that most people have is an LVAD is
implanted; they recover. Yours is a little bit different.
Dr Smedira. That has always been our paradigm, the patient re-
covery. The question is, is that the smartest and safest thing to do?
What we showed is we don’t have any negative impact by perform-
ing transplantation in patients as soon as they seem ready for it.
Dr Conte. I guess what I was looking for was more of a black
and white.
Dr Smedira. There is no black and white.
Dr L. von Segesser (Lausanne, Switzerland). When you list
a patient, how much waiting time is there?
Dr Smedira. For these patients, our median support time was
2.7 months, and for our transplant recipients, our median wait
time is 2.4 months.
Dr Von Segesser. So if you say you decided a patient was ready
now, he would have to wait how long?
Dr Smedira. A couple of weeks at most.
Dr P. Portner (Stanford, Calif). I enjoyed your presentation,
Nick. It was very interesting. I am trying to understand exactly
what you said, but you are not suggesting that in your practice,
or your combined practice, that you in fact keep patients on devices
just because they are doing well beyond the time that you could in
fact list them, and then the time to transplant is in fact whatever it
takes to receive a donor? Because there are some people who have
been suggesting that having a patient with no morbidity, extend that
period of time, although you have an ongoing potential risk, ex-
tends the time that you give them when you add that to the trans-
plantation.
Dr Smedira. I had believed in that philosophy, but now I think
that from our data we would suggest that you lose more patients by
doing that than by moving forward to transplant as soon as they are
ready.
Dr Portner. At the end of the day, though, it is a subjective de-
cision as to when you list them, right?
Dr Smedira. Yes, it always is. It is a clinical decision trying to
balance the risk of going to transplantation at this time and the risk
of events occurring on the device.
Dr Portner. In your earlier response to Jim Kirklin, with the 17
patients you have analyzed in the first month, are you suggestinggery c May 2010
Smedira et al Cardiothoracic Transplantationthat you wouldn’t even wait for that early postoperative, potentially
morbid period? You would go ahead and list them immediately or
you still have some time that you would allow for early recovery?
Dr Smedira. It depends on what the recovery is. If you have
somebody with an acute myocardial infarction, cardiogenic shock,
you put an LVAD in and 5 days later he has a creatinine of 1, he isThe Journal of Thoracic and Carsitting up, eating food, and watching the Ohio State football game,
that guy is ready for transplantation, and it has only been 9 days, but
in the past I would say, well, he has to be on the treadmill. But this
guy wasn’t ill 5 days ago and he has now recovered from an un-
eventful VAD. You move forward with the transplantation with 9
days of support.diovascular Surgery c Volume 139, Number 5 1305
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APPENDIX E1. Variables considered in the analyses
Pre-MCS
Demography: Age (y), gender, body surface area (m2), body mass index (kg/m2), height (cm), weight (kg),
weight-to-height ratio (kg/m), race
Hemodynamics: Pulmonary artery pressure (systolic, diastolic; mmHg), cardiac index (L/min/m2), systemic blood
pressure (systolic, diastolic; mmHg)
Medical condition: Ischemic or idiopathic dilated versus other cardiomyopathy, previous myocardial infarction,
previous cardiac operation, implantable cardioverter-defibrillator, medical condition at time
of MCS initiation (ICU, in-hospital but not ICU, not hospitalized, home on VAD)
Noncardiac comorbidity*: Serum creatinine (mg/dL), total bilirubin (mg/dL), blood urea nitrogen (mg/dL), hematocrit (%),
ventricular tachycardia or fibrillation
Temporary support pre-MCSy: Intraaortic balloon pump, intravenous inotropes, ventilation
PRA: Pre-MCS cytotoxic T-PRA, cytotoxic B-PRA
Experience: Time from January 1, 1991 to date of MCS
During MCS
Mode of MCS: LVAD, right ventricular assist device, ECMO, biventricular assist device, total artificial heart,
type of device, number of modes of MCS
Device sequence: LVAD to non-LVAD, non-LVAD to LVAD, cumulative time on MCS, duration of
preceding MCS
Adverse events and cumulative number of events: Neurologic, blood stream infection, pump-pocket infection, driveline infection, other infection,
reoperation for bleeding, device failure
Pre-Transplant (in addition to preceding variables)
Medical condition: Medical condition at time of transplant (ICU, in-hospital but not ICU, not hospitalized)
Noncardiac comorbidity: Serum creatinine (mg/dL), total bilirubin (mg/dL), blood urea nitrogen (mg/dL),
hemoglobin (mg/dL)
Highest PRA: Cytotoxic T-PRA, B-PRA on MCS, pre-transplant cytotoxic T-PRA, B-PRA
Sensitization: Global sensitization (see text for definition)
MCS, Mechanical circulatory support; ICU, intensive care unit; ECMO, extracorporeal membrane oxygenation; VAD, ventricular assist device; LVAD, left ventricular assist device;
PRA, panel reactive antibody; T-PRA, T-cell panel reactive antibody; B-PRA, B-cell panel reactive antibody. *Within 72 h of implantation. yWithin 72 h of implantation.
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FIGURE E1. Overall survival on MCS, with patients censored at transplant. Each symbol represents a death, vertical bars represent 68% confidence limits
(equivalent to 1 standard error), and numbers in parentheses represent patients remaining at risk.
FIGURE E2. Survival after transplant of patients surviving MCS. Format is as in Figure E1.
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FIGUREE3. Survival onMCS. Solid line is point estimate based on Table 2, and dashed lines are 68% confidence limits from modulated renewal analyses.
A, Baseline patient has MCS initiated with a non-LVAD device for 2 weeks and then requires LVAD support. B, Baseline patient has MCS initiated with an
LVAD, but at 2 months requires non-LVAD support.
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FIGURE E4. Predicted probability of surviving both MCS and transplant to 5 years after initiating MCS according to duration of MCS. Dashed lines are
estimated 68% confidence limits.
FIGURE E5. Competing risks of remaining alive on MCS, dying on MCS, and undergoing transplantation. All probabilities add to 100%. Thus, for ex-
ample, ‘‘Alive on MCS’’ is equivalent to the distribution times on MCS.
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